Saturday, December 6, 2025

Life Over War: Kim Jong Un Finally Abandons Missiles To Choose Factories And Food For His People

Kim Jong Un inspected local industrial factories to assess progress, emphasizing modernization and operational readiness for development.

BLIND and Dumb: Kim Jong Un Analyzed The ENTIRE Trump Team—And Trump Still Thinks Kim Just Needs A ‘Friendly Chat’

Kim Jong Un is open to U.S. dialogue, with March's military exercises seen as pivotal. North Korea is enhancing ties with Russia and China.

LG CNS Teams Up with S-OIL for AI-Driven Smart Factory Revolution

LG CNS partners with S-OIL to implement AI technology for smart factories, enhancing safety and efficiency in refinery operations.

Tag: obesity treatment

North KoreaKoreaKimSouth KoreaMilitaryAImarketchinaRussia

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.